 | • レポートコード：MRC23Q35935 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のうつ病治療薬市場について調査・分析し、世界のうつ病治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（SSRI、SNRI、その他）、用途別セグメント分析（病院、クリニック、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Intellipharmaceutics、Pfizer、Eli Lilly、Astrazeneca、Lundbeck、Allergan、GSK、Otsuka Pharmaceutical、Takeda、NHU Group、Shionogi、APOTEX、Kanghong Pharma、HUAHAIなどが含まれています。世界のうつ病治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、うつ病治療薬市場規模を推定する際に考慮しました。本レポートは、うつ病治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、うつ病治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・うつ病治療薬市場の概要 - うつ病治療薬のタイプ別セグメント - 世界のうつ病治療薬市場規模：タイプ別分析（SSRI、SNRI、その他） - うつ病治療薬の用途別セグメント - 世界のうつ病治療薬市場規模：用途別分析（病院、クリニック、その他） - 世界のうつ病治療薬市場規模予測（2018年-2029年） ・うつ病治療薬市場の成長トレンド - うつ病治療薬の地域別市場規模（2018年-2029年） - うつ病治療薬市場ダイナミクス - うつ病治療薬の業界動向 - うつ病治療薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：SSRI、SNRI、その他 - 世界のうつ病治療薬のタイプ別市場規模（2018年-2023年） - 世界のうつ病治療薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、クリニック、その他 - 世界のうつ病治療薬の用途別市場規模（2018年-2023年） - 世界のうつ病治療薬の用途別市場規模（2024年-2029年） ・うつ病治療薬の地域別市場規模 - 北米のうつ病治療薬市場規模（2018年-2029年） - アメリカのうつ病治療薬市場規模（2018年-2029年） - ヨーロッパのうつ病治療薬市場規模（2018年-2029年） - アジア太平洋のうつ病治療薬市場規模（2018年-2029年） - 中国のうつ病治療薬市場規模（2018年-2029年） - 日本のうつ病治療薬市場規模（2018年-2029年） - 韓国のうつ病治療薬市場規模（2018年-2029年） - インドのうつ病治療薬市場規模（2018年-2029年） - オーストラリアのうつ病治療薬市場規模（2018年-2029年） - 中南米のうつ病治療薬市場規模（2018年-2029年） - 中東・アフリカのうつ病治療薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Intellipharmaceutics、Pfizer、Eli Lilly、Astrazeneca、Lundbeck、Allergan、GSK、Otsuka Pharmaceutical、Takeda、NHU Group、Shionogi、APOTEX、Kanghong Pharma、HUAHAI ・アナリストの観点/結論 ・調査方法とデータソース |
Depression is a mental health issue. It’s a condition that starts most often in early adulthood. It’s also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used for Depression.
Highlights
The global Depression Drugs market was valued at US$ 17670 million in 2022 and is anticipated to reach US$ 20980 million by 2029, witnessing a CAGR of 2.9% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Depression Drugs key players include Intellipharmaceutics, Pfizer, Eli Lilly, Astrazeneca, Lundbeck, etc. Global top five manufacturers hold a share over 35%.
North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share about 50%.
In terms of product, SSRIs is the largest segment, with a share over 45%. And in terms of application, the largest application is Hospitals, followed by Clinics, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Depression Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Depression Drugs.
The Depression Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Depression Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Depression Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Intellipharmaceutics
Pfizer
Eli Lilly
Astrazeneca
Lundbeck
Allergan
GSK
Otsuka Pharmaceutical
Takeda
NHU Group
Shionogi
APOTEX
Kanghong Pharma
HUAHAI
Segment by Type
SSRIs
SNRIs
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Depression Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Depression Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 SSRIs
1.2.3 SNRIs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Depression Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Depression Drugs Market Perspective (2018-2029)
2.2 Depression Drugs Growth Trends by Region
2.2.1 Global Depression Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Depression Drugs Historic Market Size by Region (2018-2023)
2.2.3 Depression Drugs Forecasted Market Size by Region (2024-2029)
2.3 Depression Drugs Market Dynamics
2.3.1 Depression Drugs Industry Trends
2.3.2 Depression Drugs Market Drivers
2.3.3 Depression Drugs Market Challenges
2.3.4 Depression Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Depression Drugs Players by Revenue
3.1.1 Global Top Depression Drugs Players by Revenue (2018-2023)
3.1.2 Global Depression Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Depression Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Depression Drugs Revenue
3.4 Global Depression Drugs Market Concentration Ratio
3.4.1 Global Depression Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Depression Drugs Revenue in 2022
3.5 Depression Drugs Key Players Head office and Area Served
3.6 Key Players Depression Drugs Product Solution and Service
3.7 Date of Enter into Depression Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Depression Drugs Breakdown Data by Type
4.1 Global Depression Drugs Historic Market Size by Type (2018-2023)
4.2 Global Depression Drugs Forecasted Market Size by Type (2024-2029)
5 Depression Drugs Breakdown Data by Application
5.1 Global Depression Drugs Historic Market Size by Application (2018-2023)
5.2 Global Depression Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Depression Drugs Market Size (2018-2029)
6.2 North America Depression Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Depression Drugs Market Size by Country (2018-2023)
6.4 North America Depression Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Depression Drugs Market Size (2018-2029)
7.2 Europe Depression Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Depression Drugs Market Size by Country (2018-2023)
7.4 Europe Depression Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Depression Drugs Market Size (2018-2029)
8.2 Asia-Pacific Depression Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Depression Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Depression Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Depression Drugs Market Size (2018-2029)
9.2 Latin America Depression Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Depression Drugs Market Size by Country (2018-2023)
9.4 Latin America Depression Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Depression Drugs Market Size (2018-2029)
10.2 Middle East & Africa Depression Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Depression Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Depression Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Intellipharmaceutics
11.1.1 Intellipharmaceutics Company Detail
11.1.2 Intellipharmaceutics Business Overview
11.1.3 Intellipharmaceutics Depression Drugs Introduction
11.1.4 Intellipharmaceutics Revenue in Depression Drugs Business (2018-2023)
11.1.5 Intellipharmaceutics Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Depression Drugs Introduction
11.2.4 Pfizer Revenue in Depression Drugs Business (2018-2023)
11.2.5 Pfizer Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Depression Drugs Introduction
11.3.4 Eli Lilly Revenue in Depression Drugs Business (2018-2023)
11.3.5 Eli Lilly Recent Development
11.4 Astrazeneca
11.4.1 Astrazeneca Company Detail
11.4.2 Astrazeneca Business Overview
11.4.3 Astrazeneca Depression Drugs Introduction
11.4.4 Astrazeneca Revenue in Depression Drugs Business (2018-2023)
11.4.5 Astrazeneca Recent Development
11.5 Lundbeck
11.5.1 Lundbeck Company Detail
11.5.2 Lundbeck Business Overview
11.5.3 Lundbeck Depression Drugs Introduction
11.5.4 Lundbeck Revenue in Depression Drugs Business (2018-2023)
11.5.5 Lundbeck Recent Development
11.6 Allergan
11.6.1 Allergan Company Detail
11.6.2 Allergan Business Overview
11.6.3 Allergan Depression Drugs Introduction
11.6.4 Allergan Revenue in Depression Drugs Business (2018-2023)
11.6.5 Allergan Recent Development
11.7 GSK
11.7.1 GSK Company Detail
11.7.2 GSK Business Overview
11.7.3 GSK Depression Drugs Introduction
11.7.4 GSK Revenue in Depression Drugs Business (2018-2023)
11.7.5 GSK Recent Development
11.8 Otsuka Pharmaceutical
11.8.1 Otsuka Pharmaceutical Company Detail
11.8.2 Otsuka Pharmaceutical Business Overview
11.8.3 Otsuka Pharmaceutical Depression Drugs Introduction
11.8.4 Otsuka Pharmaceutical Revenue in Depression Drugs Business (2018-2023)
11.8.5 Otsuka Pharmaceutical Recent Development
11.9 Takeda
11.9.1 Takeda Company Detail
11.9.2 Takeda Business Overview
11.9.3 Takeda Depression Drugs Introduction
11.9.4 Takeda Revenue in Depression Drugs Business (2018-2023)
11.9.5 Takeda Recent Development
11.10 NHU Group
11.10.1 NHU Group Company Detail
11.10.2 NHU Group Business Overview
11.10.3 NHU Group Depression Drugs Introduction
11.10.4 NHU Group Revenue in Depression Drugs Business (2018-2023)
11.10.5 NHU Group Recent Development
11.11 Shionogi
11.11.1 Shionogi Company Detail
11.11.2 Shionogi Business Overview
11.11.3 Shionogi Depression Drugs Introduction
11.11.4 Shionogi Revenue in Depression Drugs Business (2018-2023)
11.11.5 Shionogi Recent Development
11.12 APOTEX
11.12.1 APOTEX Company Detail
11.12.2 APOTEX Business Overview
11.12.3 APOTEX Depression Drugs Introduction
11.12.4 APOTEX Revenue in Depression Drugs Business (2018-2023)
11.12.5 APOTEX Recent Development
11.13 Kanghong Pharma
11.13.1 Kanghong Pharma Company Detail
11.13.2 Kanghong Pharma Business Overview
11.13.3 Kanghong Pharma Depression Drugs Introduction
11.13.4 Kanghong Pharma Revenue in Depression Drugs Business (2018-2023)
11.13.5 Kanghong Pharma Recent Development
11.14 HUAHAI
11.14.1 HUAHAI Company Detail
11.14.2 HUAHAI Business Overview
11.14.3 HUAHAI Depression Drugs Introduction
11.14.4 HUAHAI Revenue in Depression Drugs Business (2018-2023)
11.14.5 HUAHAI Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details